000 | 01961 a2200553 4500 | ||
---|---|---|---|
005 | 20250517000443.0 | ||
264 | 0 | _c20150401 | |
008 | 201504s 0 0 eng d | ||
022 | _a1365-2141 | ||
024 | 7 |
_a10.1111/bjh.13150 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aNikonova, Anna | |
245 | 0 | 0 |
_aPredictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. _h[electronic resource] |
260 |
_bBritish journal of haematology _cFeb 2015 |
||
300 |
_a492-500 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
650 | 0 | 4 | _aBiopsy, Fine-Needle |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 | _aComorbidity |
650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
650 | 0 | 4 |
_aDelayed Diagnosis _xadverse effects |
650 | 0 | 4 | _aDisease-Free Survival |
650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aKaplan-Meier Estimate |
650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdiagnosis |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aOntario _xepidemiology |
650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aRadiotherapy, Adjuvant |
650 | 0 | 4 | _aReferral and Consultation |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aRituximab |
650 | 0 | 4 | _aSocioeconomic Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aVincristine _xadministration & dosage |
700 | 1 | _aGuirguis, Hany R | |
700 | 1 | _aBuckstein, Rena | |
700 | 1 | _aCheung, Matthew C | |
773 | 0 |
_tBritish journal of haematology _gvol. 168 _gno. 4 _gp. 492-500 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.13150 _zAvailable from publisher's website |
999 |
_c24286948 _d24286948 |